Edition:
United Kingdom

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

6,049.00GBp
11 Dec 2018
Change (% chg)

42.00 (+0.70%)
Prev Close
6,007.00
Open
6,012.00
Day's High
6,063.00
Day's Low
6,003.00
Volume
416,501
Avg. Vol
1,934,189
52-wk High
6,432.48
52-wk Low
4,544.50

Latest Key Developments (Source: Significant Developments)

Astrazeneca Says Divestment Of Rights To Covis Completed
Thursday, 6 Dec 2018 

Dec 6 (Reuters) - AstraZeneca PLC ::DIVESTMENT OF RIGHTS TO COVIS COMPLETED.  Full Article

Dynavax Technologies-AstraZeneca Informed Co Initial High-Level Results From Phase 2A Study Indicate Azd1419 Treatment Did Not Meet Primary Endpoint
Thursday, 29 Nov 2018 

Nov 29 (Reuters) - Dynavax Technologies Corp ::DYNAVAX TECHNOLOGIES - ASTRAZENECA INFORMED CO INITIAL HIGH-LEVEL RESULTS FROM PHASE 2A STUDY INDICATE AZD1419 TREATMENT DID NOT MEET PRIMARY ENDPOINT.DYNAVAX TECHNOLOGIES CORP - ASTRAZENECA WILL NOW REVIEW FULL DATA BEFORE DECIDING ON NEXT STEPS FOR AZD1419 PROGRAM.DYNAVAX TECHNOLOGIES SAYS AZD1419 TREATMENT APPEARED TO BE SAFE & WELL TOLERATED & STUDY CONFIRMED ACTIVATION OF TLR9 PATHWAY - SEC FILING.  Full Article

Biocartis Group And AstraZeneca Enter Into Agreement Aimed At Faster Lung Cancer Biomarker Results
Thursday, 29 Nov 2018 

Nov 29 (Reuters) - BIOCARTIS GROUP NV ::BIOCARTIS GROUP NV: BIOCARTIS AND ASTRAZENECA ENTER INTO AGREEMENT AIMED AT FASTER LUNG CANCER BIOMARKER RESULTS.PROSPECTIVE LUNG CANCER STUDY WITH IDYLLA(TM) EGFR MUTATION TEST (CE-IVD) WILL BE CONDUCTED IN SELECTED EUROPEAN COUNTRIES..STUDY IS AIMED AT DEMONSTRATING HOW UNIQUE FEATURES OF IDYLLA(TM) PLATFORM CAN OVERCOME CURRENT COMPLEXITY AND LONG TURNAROUND TIME FOR LUNG CANCER PATIENTS.STUDY WILL BE INITIATED AT MORE THAN A DOZEN SITES IN BELGIUM, FRANCE, GERMANY AND ITALY..  Full Article

Astrazeneca's Imfinzi Fails To Meet Primary Endpoint In Late-Stage Mystic Trial
Friday, 16 Nov 2018 

Nov 16 (Reuters) - AstraZeneca PLC ::ASTRAZENECA PLC - ASTRAZENECA PROVIDES UPDATE ON PHASE III MYSTIC.SAYS UPDATE ON PHASE III MYSTIC TRIAL OF IMFINZI AND TREMELIMUMAB IN STAGE IV NON-SMALL CELL LUNG CANCER.SAYS OS RESULT DID NOT MEET STATISTICAL SIGNIFICANCE.SAYS IN PRIMARY ANALYSIS POPULATION OF PATIENTS, IMFINZI MONOTHERAPY & COMBINATION OF IMFINZI PLUS TREMELIMUMAB DID NOT MEET PRIMARY ENDPOINTS.SAYS SAFETY AND TOLERABILITY PROFILES FOR IMFINZI AND IMFINZI PLUS TREMELIMUMAB COMBINATION WERE CONSISTENT WITH PREVIOUS TRIALS.  Full Article

AstraZeneca To Divest U.S. Synagis Rights To Swedish Orphan Biovitrum
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - AstraZeneca PLC ::ASTRAZENECA TO DIVEST US SYNAGIS RIGHTS TO SOBI.PROPOSED DEAL FOR UPFRONT CONSIDERATION OF $1.5BN PLUS FURTHER CONTINGENT PAYMENTS.TRANSACTION GRANTS SOBI RIGHT TO PARTICIPATE IN US PROFITS AND LOSSES FOR MEDI8897.SOBI WILL COMMERCIALISE SYNAGIS IN US AND AROUND 130 ASTRAZENECA EMPLOYEES WILL TRANSFER TO SOBI AS PART OF DEAL.WILL ALSO GET UP TO $470M IN SALES-RELATED PAYMENTS FOR SYNAGIS, $175M MILESTONE AFTER BLA SUBMISSION FOR MEDI8897.  Full Article

Sobi to buy Synagis U.S. rights from Astrazeneca, pays $1.5 bln upfront
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Swedish Orphan Biovitrum ::SOBI™ TO ACQUIRE SYNAGIS® US RIGHTS FROM ASTRAZENECA - CREATES A PLATFORM FOR GLOBAL GROWTH.SAYS ENTERED INTO AGREEMENTS TO ACQUIRE PERPETUAL RIGHTS TO SYNAGIS® (PALIVIZUMAB) IN US FROM ASTRAZENECA AND TO PARTICIPATE IN 50 PER CENT OF FUTURE EARNINGS OF CANDIDATE DRUG MEDI8897 IN US.SAYS TOTAL UPFRONT CONSIDERATION CORRESPONDS TO USD 1,500 M (SEK 13.6 B.SAYS PAYMENT CONSISTING OF USD 1,000 M (SEK 9.1 B) IN CASH AND USD 500 M (SEK 4.5 B) EQUIVALENT IN NEWLY ISSUED SOBI SHARES.SAYS FOLLOWING COMPLETION OF ACQUISITION, ASTRAZENECA WILL HOLD 8.1 PER CENT OF TOTAL SHARES AND VOTES IN SOBI.SAYS SIGNIFICANT TOP LINE ADDITION WILL GIVE SOBI SUBSTANTIAL RECURRING EARNINGS TO FURTHER ADVANCE US EXPANSION AND ENABLE FUTURE STRATEGIC ACQUISITIONS OVER MID-TERM, POSITIONING COMPANY WELL FOR ITS NEXT PHASE OF GROWTH.SAYS WILL ALSO PAY USD 20 M (SEK 181 M) IN CASH, PER YEAR, FOR THREE YEARS 2019-2021 AS CONSIDERATION FOR MEDI8897.SAYS MAY PAY UP TO USD 470 M (SEK 4.3 B) FOR SYNAGIS SALES-RELATED MILESTONES FROM 2026 ONWARDS, PLUS, USD 175 M (SEK 1.6 B) FOLLOWING SUBMISSION OF BIOLOGICS LICENSE APPLICATION (BLA) TO US FOOD AND DRUG ADMINISTRATION (FDA) FOR MEDI8897.SAYS AGREEMENT ALSO INCLUDES POTENTIAL NET PAYMENTS OF APPROXIMATELY USD 110 M (SEK 1.0 B) ON ACHIEVEMENT OF OTHER MEDI8897 PROFIT AND DEVELOPMENT-RELATED MILESTONES.SAYS COMPLETION OF ACQUISITION IS SUBJECT TO CERTAIN CUSTOMARY CONDITIONS AND REGULATORY APPROVALS.  Full Article

Astrazeneca Posts Additional Financial Information-Grünenthal Deal
Wednesday, 31 Oct 2018 

Oct 31 (Reuters) - AstraZeneca PLC ::ASTRAZENECA PLC - ADDITIONAL FINANCIAL INFORMATION-GRÜNENTHAL DEAL.ASTRAZENECA PLC - BOOK VALUE OF GROSS ASSETS SUBJECT TO DIVESTMENTS WAS APPROXIMATELY $99 MILLION AT 31 DECEMBER 2017.ASTRAZENECA PLC - IN YEAR TO 31 DECEMBER 2017 AGGREGATE PRE-TAX PROFITS ATTRIBUTABLE TO NEXIUM AND VIMOVO IN RELEVANT TERRITORIES WERE $203 MILLION.  Full Article

Grünenthal Agrees $922 Mln Deal With Astrazeneca For Nexium & Vimovo
Tuesday, 30 Oct 2018 

Oct 30 (Reuters) - Grünenthal :GRÜNENTHAL AGREES US$ 922 M DEAL WITH ASTRAZENECA FOR NEXIUM AND VIMOVO.GRÜNENTHAL - AGREED TO BUY ASTRAZENECA'S EUROPEAN RIGHTS TO NEXIUM AND GLOBAL (EX US AND JAPAN) RIGHTS TO VIMOVO FOR UP TO US$922 M.GRÜNENTHAL - WITH ACQUISITION, GRÜNENTHAL IS EXPECTED TO DOUBLE ITS EBITDA PERFORMANCE.GRÜNENTHAL - FINANCING FOR GRÜNENTHAL HAS BEEN SECURED BY UNDERWRITING BANKS BBVA, BNP PARIBAS, COMMERZBANK AND ING.  Full Article

Astrazeneca PLC Reports 12.6 Pct Stake In Phasebio Pharmaceuticals
Monday, 29 Oct 2018 

Oct 29 (Reuters) - AstraZeneca PLC ::ASTRAZENECA PLC REPORTS 12.6 PERCENT STAKE IN PHASEBIO PHARMACEUTICALS INC AS OF OCTOBER 17 - SEC FILING.ASTRAZENECA PLC - ACQUIRED SHARES OF PHASEBIO PHARMACEUTICALS INC BECAUSE OF BELIEF THAT SECURITIES REPRESENT AN ATTRACTIVE INVESTMENT.  Full Article

Astrazeneca Says Phase III HARMONIZE Global trial of Lokelma confirms efficacy in maintaining normal potassium levels in Asian patients with hyperkalaemia
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - AstraZeneca PLC ::ASTRAZENECA -PHASE III HARMONIZE GLOBAL TRIAL OF LOKELMA CONFIRMS EFFICACY IN MAINTAINING NORMAL POTASSIUM LEVELS IN ASIAN PATIENTS WITH HYPERKALAEMIA.SAYS SAFETY PROFILE OF LOKELMA OBSERVED IN HARMONIZE GLOBAL WAS CONSISTENT WITH PREVIOUS TRIALS.DATA FROM HARMONIZE GLOBAL PHASE III TRIAL WILL SUPPORT REGISTRATION IN JAPAN, KOREA, TAIWAN AND RUSSIA.  Full Article

UPDATE 1-Moderna, largest biotech to go public, fails to impress in market debut

Dec 7 Moderna Inc's shares fell as much as 6 percent in an upsized market debut on Friday, taking a hit from a broader selloff in U.S. markets spurred by investor concerns over an economic slowdown amid renewed trade tensions.